Great article, would you like

1
Comment
Favorite

Great article, would you like to share it?

Regeneron Pharma 4Q Profit Falls as Higher R&D Weighs

Regeneron Pharmaceuticals profit fell in the fourth quarter, despite higher revenue, on the back of higher research-and-development expenses.

Regeneron Pharma 4Q Profit Falls as Higher R&D Weighs

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":527377812034664,"tweetId":"527377812034664","gmtCreate":1769776528618,"gmtModify":1769776532029,"author":{"id":4231039849485302,"idStr":"4231039849485302","authorId":4231039849485302,"authorIdStr":"4231039849485302","name":"cececinok","avatar":"https://community-static.tradeup.com/news/4bf39702e227104035d81ab1d9e856e9","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body>Great article, would you like to share it?</body></html>","htmlText":"<html><head></head><body>Great article, would you like to share it?</body></html>","text":"Great article, would you like to share it?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/527377812034664","repostId":2607017465,"repostType":4,"repost":{"id":"2607017465","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1769776369,"share":"https://ttm.financial/m/news/2607017465?lang=en_US&edition=fundamental","pubTime":"2026-01-30 20:32","market":"us","language":"en","title":"Regeneron Pharma 4Q Profit Falls as Higher R&D Weighs","url":"https://stock-news.laohu8.com/highlight/detail?id=2607017465","media":"Dow Jones","summary":"Regeneron Pharmaceuticals profit fell in the fourth quarter, despite higher revenue, on the back of higher research-and-development expenses.","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> profit fell in the fourth quarter, despite higher revenue, on the back of higher research-and-development expenses.</p><p>The biotechnology company posted on Friday a lower net income of $845 million, or $7.86 a share, compared with $918 million, or $8.06 a share, in the same quarter a year earlier.</p><p>Adjusted earnings came to $11.44 a share. According to FactSet, analysts were expecting $10.74 a share.</p><p>Total revenue rose 3% to $3.88 billion, topping analyst forecasts of $3.81 billion.</p><p>R&amp;D expenses rose 15% to $1.63 billion in the quarter.</p><p>For 2026, Regeneron estimates R&amp;D expenses to be in the range of $6.45 billion to $6.68 billion, and when adjusting for stock-based compensation expenses, the range is forecasted at between $5.9 billion and $6.1 billion.</p><p>Chief Financial Officer Christopher Fenimore said the company&#39;s priorities this year remain on internal investments, evaluating complementary business-development opportunities, and capital returns through share repurchases and dividends.</p><p>Shares were down 2.1% to $733.49 in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2a494c4fcad22c7ec2e44e4ccfb1e917\" tg-width=\"537\" tg-height=\"158\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharma 4Q Profit Falls as Higher R&D Weighs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharma 4Q Profit Falls as Higher R&D Weighs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-30 20:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> profit fell in the fourth quarter, despite higher revenue, on the back of higher research-and-development expenses.</p><p>The biotechnology company posted on Friday a lower net income of $845 million, or $7.86 a share, compared with $918 million, or $8.06 a share, in the same quarter a year earlier.</p><p>Adjusted earnings came to $11.44 a share. According to FactSet, analysts were expecting $10.74 a share.</p><p>Total revenue rose 3% to $3.88 billion, topping analyst forecasts of $3.81 billion.</p><p>R&amp;D expenses rose 15% to $1.63 billion in the quarter.</p><p>For 2026, Regeneron estimates R&amp;D expenses to be in the range of $6.45 billion to $6.68 billion, and when adjusting for stock-based compensation expenses, the range is forecasted at between $5.9 billion and $6.1 billion.</p><p>Chief Financial Officer Christopher Fenimore said the company&#39;s priorities this year remain on internal investments, evaluating complementary business-development opportunities, and capital returns through share repurchases and dividends.</p><p>Shares were down 2.1% to $733.49 in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2a494c4fcad22c7ec2e44e4ccfb1e917\" tg-width=\"537\" tg-height=\"158\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","BK4139":"生物科技","REGN":"再生元制药公司","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4588":"碎股","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2607017465","content_text":"Regeneron Pharmaceuticals profit fell in the fourth quarter, despite higher revenue, on the back of higher research-and-development expenses.The biotechnology company posted on Friday a lower net income of $845 million, or $7.86 a share, compared with $918 million, or $8.06 a share, in the same quarter a year earlier.Adjusted earnings came to $11.44 a share. According to FactSet, analysts were expecting $10.74 a share.Total revenue rose 3% to $3.88 billion, topping analyst forecasts of $3.81 billion.R&D expenses rose 15% to $1.63 billion in the quarter.For 2026, Regeneron estimates R&D expenses to be in the range of $6.45 billion to $6.68 billion, and when adjusting for stock-based compensation expenses, the range is forecasted at between $5.9 billion and $6.1 billion.Chief Financial Officer Christopher Fenimore said the company's priorities this year remain on internal investments, evaluating complementary business-development opportunities, and capital returns through share repurchases and dividends.Shares were down 2.1% to $733.49 in premarket trading.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":14,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":35,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}